Premenstrual Dysphoric Disorder (PMDD)

Severe Mood Symptoms in the Luteal Phase: Diagnosis and Treatment

Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome characterized by significant mood, behavioral, and physical symptoms in the week before menses, with symptom resolution shortly after menstruation begins. PMDD was added to the DSM-5 in 2013 after decades of clinical recognition that severe premenstrual mood symptoms cause substantial impairment distinct from ordinary PMS. The disorder affects 3–8% of menstruating women and is highly responsive to specific treatments.

Key Facts

  • Prevalence: 3–8% of menstruating women
  • Onset typically in mid-20s; can begin at any reproductive age
  • Symptoms cluster in the luteal phase, resolve within days of menses onset
  • Caused by abnormal central nervous system response to normal hormonal fluctuations, not abnormal hormone levels
  • SSRIs are highly effective; can be taken continuously or only luteal phase
  • Strong link to perinatal depression and perimenopausal mood symptoms

DSM-5 Diagnostic Criteria

PMDD (625.4 / N94.3) requires at least five symptoms in the final week before menses, beginning to improve within a few days after menses, and minimal/absent in the week post-menses. At least one symptom must be from list A:

A. Affective Symptoms (≥1 required)

  1. Marked affective lability (mood swings, suddenly tearful, sensitivity)
  2. Marked irritability or anger or increased interpersonal conflicts
  3. Marked depressed mood, hopelessness, or self-deprecating thoughts
  4. Marked anxiety, tension, or feelings of being keyed up

B. Other Symptoms (combined with A to total ≥5)

  1. Decreased interest in usual activities
  2. Difficulty concentrating
  3. Lethargy, fatigue, lack of energy
  4. Marked change in appetite, overeating, or food cravings
  5. Hypersomnia or insomnia
  6. Sense of being overwhelmed or out of control
  7. Physical symptoms (breast tenderness, joint pain, bloating, weight gain)

Diagnosis requires prospective daily rating across at least two cycles — not retrospective recall, which is unreliable.

PMDD vs. PMS

  • PMS: mild physical and emotional symptoms premenstrually; tolerable; doesn't impair function. Affects ~75% of menstruating women.
  • PMDD: severe mood symptoms causing significant impairment in work, relationships, or function. ~3–8% of women.
  • The line is functional impact, not symptom presence

Why PMDD Happens

  • PMDD patients have normal hormone levels — what differs is their brain's sensitivity to hormonal change
  • Allopregnanolone (a metabolite of progesterone) modulates GABA receptors; PMDD patients show altered response
  • Serotonergic system reactivity to hormonal shifts is also altered
  • Genetic component: heritability ~50%
  • Often co-occurs with personal or family history of mood disorders
  • Strong link to "reproductive depression" pattern: PMDD, postpartum depression, perimenopausal depression

Diagnosis

  • Daily prospective rating (DRSP — Daily Record of Severity of Problems) for ≥2 cycles is required
  • Retrospective reports are unreliable; about 50% of women who report severe PMS don't meet PMDD criteria when rated prospectively
  • Rule out exacerbation of underlying mood/anxiety disorder (premenstrual exacerbation)
  • Rule out medical conditions: thyroid dysfunction, anemia, perimenopause

Treatment

SSRIs (First-Line)

  • Highly effective; response often within first cycle (faster than for depression)
  • Sertraline, fluoxetine, paroxetine, escitalopram all evidence-supported
  • Three dosing strategies: continuous, luteal phase only (cycle days 14–28), or symptom-onset
  • Luteal-phase dosing is unusual in psychiatry but works for PMDD because the mechanism is acute

Hormonal Treatment

  • Drospirenone-containing oral contraceptives (Yaz) FDA-approved for PMDD
  • Continuous (no placebo week) regimens reduce hormone fluctuations
  • GnRH agonists (Lupron) for severe refractory cases — induce reversible menopause
  • Surgical menopause (oophorectomy) reserved for severe, refractory cases

Other

  • CBT specifically adapted for PMDD shows benefit
  • Calcium (1200 mg/day) and vitamin B6 (50–100 mg/day) have modest evidence
  • Aerobic exercise reduces symptoms
  • Mindfulness-based interventions emerging

Self-Help Strategies

  • Track symptoms daily for at least 2 cycles to confirm pattern and identify your worst days
  • Plan critical work and relationship demands for the follicular phase when possible
  • Limit alcohol and caffeine premenstrually
  • Prioritize sleep, exercise, and stress reduction in the luteal phase
  • Inform partners or close colleagues about the pattern (without it becoming an excuse for lack of treatment)
  • Have a safety plan if suicidal ideation occurs premenstrually — PMDD is associated with elevated suicide risk during luteal phase

Conclusion

PMDD is a real, well-defined, and highly treatable disorder that has been undertreated for decades because severe premenstrual mood symptoms were dismissed as "bad PMS" or as women's exaggeration. Daily prospective tracking for two cycles is the diagnostic gold standard — and it's accessible to anyone. SSRIs work fast in PMDD and can be taken only in the luteal phase, which is unusual and useful. If menstrual cycles consistently bring days of severe mood symptoms that resolve with menses, this is the diagnosis to consider.

Related Topics